Key Drivers
- Strong Liquidity
- Rising Leverage
- Heavy Cash Burn
AIAI Summary
ZYME is evolving from a pure cash-burn biotech into a catalyst-driven story with the August 2026 zanidatamab PDUFA and the Theravance acquisition offering upside and a potential commercial backstop, but the key takeaway is that rising debt, continued losses, and negative free cash flow mean the stock remains a high-risk, binary execution bet.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Liquidity
- •Rising Leverage
- •Heavy Cash Burn
ZYME has strong near-term liquidity, but sharply higher leverage, steep losses, ongoing cash burn, and a rich sales multiple make the stock risky despite near-100% gross margins.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance cap
- •Mid-$24 support
ZYME is showing an improving short-term rebound, with higher lows and a move from $21.81 to $25.12 since early August, but the rally is still capped near $25.76 and needs to hold the mid-$24s to avoid another pullback.
Sharp rebound from $21.81 on 2026-08-03 followed by a pullback at resistance on 2026-08-14
Sentiment & News
Key News Insights:
- •Zanidatamab PDUFA
- •Theravance Closing
- •Cash Strength
Zymeworks' mixed Q2 results were overshadowed by the near-term zanidatamab PDUFA catalyst and the planned Theravance Biopharma acquisition, both of which could materially expand future revenue and milestone upside. #M&A
The shares are likely to be driven more by the August 25 FDA decision and the Theravance deal timeline than by the quarter's mixed earnings print
Similar Companies in Healthcare
Other companies in the same sector with AI ratings